Champions Oncology, Inc. CSBR

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
63/100
Moderate

Ranked against 712 peers in Biotechnology

About Champions Oncology, Inc.

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug … Full CSBR analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.95), suggesting sticky customer base.
  • Cash Generation Consistent Cash generation is consistent (score 0.84), indicating reliable business model.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.11), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
56
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where CSBR ranks in Biotechnology

Champions Oncology, Inc. ranks #77 of 713 scored companies in Biotechnology by moat score — the top 11%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
73 Zymeworks Inc. ZYME 63/100 Moderate
74 AnaptysBio, Inc. ANAB 63/100 Moderate
75 Genenta Science S.p.A. GNTA 63/100 Moderate
76 Protalix BioTherapeutics, Inc. PLX 63/100 Moderate
77 Champions Oncology, Inc. CSBR 63/100 Moderate
78 Sutro Biopharma, Inc. STRO 62/100 Moderate
79 Heron Therapeutics, Inc. HRTX 62/100 Moderate
80 Vanda Pharmaceuticals Inc. VNDA 62/100 Moderate
81 Denali Therapeutics Inc. DNLI 62/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How CSBR scores on the Corporate Default defenses

Pricing Power

Score 56 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 87 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 88 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 31 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 68 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 54 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CSBR's moat

What is Champions Oncology, Inc.'s moat score?

Champions Oncology, Inc. (CSBR) scores 62 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #77 of 713 scored companies in Biotechnology, the top 11%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (88/100) and its weakest is Capital Efficiency (31/100).

How does Champions Oncology, Inc. compare with other Biotechnology companies?

Champions Oncology, Inc. ranks #77 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Protalix BioTherapeutics, Inc. (PLX) at 63 just above it and Sutro Biopharma, Inc. (STRO) at 62 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Champions Oncology, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Champions Oncology, Inc.?

The Corporate Default template measures 6 defenses, and CSBR scores: Pricing Power (56), Cost Advantage (87), Customer Stickiness (88), Capital Efficiency (31), Resilience (68), Scale & Market Position (54). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000